Dyne Therapeutics, Inc. DYN Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $753.1M+59.5% | $893.37M+105% | $573.61M+7.8% | $485.04M-20.2% | $472.26M+73.6% | ||
| $219.05M+6.7% | $217.19M+5.0% | $218.28M+14.0% | $198.89M+16.6% | $205.24M+13.1% | ||
| $48.87M+307% | $16.03M-5.8% | $14.38M+13.1% | $14.03M+4.0% | $12.01M-65.3% | ||
| $1.02B+48.1% | $1.13B+70.9% | $806.26M+9.5% | $697.95M-11.9% | $689.5M+41.3% | ||
| $23.68M+312% | $24.03M+345% | $23.97M+390% | $5.68M+13.0% | $5.75M+25.5% | ||
| $19.65M-17.7% | $20.74M-15.7% | $21.82M-14.8% | $22.86M-14.1% | $23.88M-13.6% | ||
| $1.08B+49.8% | $1.19B+71.7% | $867.06M+12.8% | $728.99M-11.7% | $721.07M+38.1% | ||
| $10.78M+53.6% | $8.08M+23.2% | $12.06M+95.9% | $14.02M+642% | $7.02M-2.7% | ||
| $29.21M+34.3% | $37.55M+21.7% | $42.75M+32.4% | $22.45M-2.7% | $21.75M+109% | ||
| $5.03M-1.5% | $5M+3.0% | $5.04M+4.7% | $5M+4.7% | $5.11M+7.5% | ||
| $51.25M+51.3% | $50.63M+19.8% | $59.85M+38.3% | $41.47M+39.4% | $33.88M+51.5% | ||
| $149.38M— | $148.92M— | $99.15M— | $98.81M— | —— | ||
| $14.27M-21.7% | $15.28M-20.1% | $16.28M-18.8% | $17.26M-17.6% | $18.22M-16.7% | ||
| $214.9M+312% | $214.83M+250% | $175.28M+177% | $157.55M+211% | $52.1M+17.8% | ||
| —— | $0— | $0— | $0— | $0— | ||
| $16K+45.5% | $16K+60.0% | $14K+40.0% | $11K+10.0% | $11K+22.2% | ||
| $2.38B+37.4% | $2.37B+49.9% | $1.98B+26.2% | $1.75B+13.6% | $1.73B+47.4% | ||
| -$1.52B-42.4% | -$1.4B-47.0% | -$1.28B-49.3% | -$1.18B-54.1% | -$1.07B-52.6% | ||
| -$137K-157% | $475K+7,817% | $496K+3.8% | $252K+205% | $241K+283% | ||
| $865.06M+29.3% | $972.13M+54.3% | $691.78M-1.9% | $571.45M-26.3% | $668.97M+39.9% | ||
| $1.08B+49.8% | $1.19B+71.7% | $867.06M+12.8% | $728.99M-11.7% | $721.07M+38.1% | ||
| $219.05M+6.7% | $217.19M+5.0% | $218.28M+14.0% | $198.89M+16.6% | $205.24M+13.1% | ||
| $19.65M-17.7% | $20.74M-15.7% | $21.82M-14.8% | $22.86M-14.1% | $23.88M-13.6% | ||
| $19.65M-17.7% | $20.74M-15.7% | $21.82M-14.8% | $22.86M-14.1% | $23.88M-13.6% | ||
| $15.59M+703% | $15.6M+703% | $15.01M+675% | $2.51M+30.2% | $1.94M+1.1% | ||
| $19.65M-17.7% | $20.74M-15.7% | $21.82M-14.8% | $22.86M-14.1% | $23.88M-13.6% | ||
| $6.22M— | —— | —— | —— | —— | ||
| $29.21M+34.3% | $37.55M+21.7% | $42.75M+32.4% | $22.45M-2.7% | $21.75M+109% | ||
| $168.68M+623% | $169.2M+605% | $120.47M+385% | $121.08M+371% | $23.33M-12.3% | ||
| $16K+45.5% | $16K+60.0% | $14K+40.0% | $11K+10.0% | $11K+22.2% | ||
| —— | $0— | $0— | $0— | $0— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Dyne Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 19.92 — current assets exceed current liabilities.
- Where does Dyne Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Dyne Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.